[ RadSafe ] Interesting study with a potential radiation mitigating drug

[JPreisig at aol.com]

Colette/Radsafe:
 
     Thanks for the explanation, Colette.  Sadly,  it reminds me a bit 
about Dr. Gray (UCLA???) and others trying to save lives  after Chernobyl.
 
     Joe Preisig
 
 
In a message dated 1/23/2015 3:45:17 P.M. Eastern Standard Time,  
Colette.Tremblay at ssp.ulaval.ca writes:

Hi  Joe,

The investigators used a chemical named DBIBB to mitigates in mice  the 
injuries caused by high-dose ionizing radiation. 

The substance,  when administered up to 72 hours postirradiation, reduced 
mortality in mice.  DBIBB mitigated the gastrointestinal radiation syndrome, 
reduced programmed  cell death and enhanced DNA repair in the animals. DBIBB 
also increased the  survival of mice suffering from the hematopoietic acute 
radiation syndrome  after total-body irradiation. 

The endpoint of the study was mortality  at day 30 following a 15 Gy whole 
body dose. In the control  group, only  one mouse
out of 14 per group survived to day 30 (93% lethality), and the  mean 
survival time was 8 days. In a group receiving low dose DBIBB (1 mg/kg,  26 hour 
after irradiation), 2 mice were alive at day 30 and the mean survival  time 
was 15 days. In the high dose group (10 mg/kg), 10 out of 14 mice were  
alive on day 30. It opens up the possibility of future treatments that could  
administered hours, even days, after  irradiation.

Colette

-----Message d'origine-----
De :  radsafe-bounces at health.phys.iit.edu  
[mailto:radsafe-bounces at health.phys.iit.edu] De la part de  JPreisig at aol.com
Envoyé : 22 janvier 2015 16:29
À :  radsafe at health.phys.iit.edu
Objet : Re: [ RadSafe ] Interesting study  with a potential radiation 
mitigating drug

Colette,

What does all that mean???

Joe  Preisig




In a message dated 1/22/2015 3:44:42 P.M. Eastern  Standard Time, 
Colette.Tremblay at ssp.ulaval.ca writes:

The   citation is :

Patil et al., Combined Mitigation of the  Gastrointestinal  and 
Hematopoietic Acute Radiation Syndromes by an LPA2  Receptor-Specific  Nonlipid 
Agonist, Chemistry & Biology  (2015),
http://dx.doi.org/10.1016/j.chembiol.2014.12.009

The  complete paper is  available free of charge (see link at the end of  
the
citation)

Colette

[cid:image001.gif at 01D0365A.37F58C20]

[cid:image002.gif at 01D0365A.37F58C20]

[cid:image004.gif at 01D0365A.37F58C20]<http://www.ulaval.ca/>




Colette   Tremblay
Spécialiste en radioprotection
Service de sécurité et de   prévention
Pavillon Ernest-Lemieux, local 1533
Poste    2893

Avis  de
confidentialité<http://www.rec.ulaval.ca/lce/securite/confidentialite.htm>


_______________________________________________
You   are currently subscribed to the RadSafe mailing list

Before posting  a  message to RadSafe be sure to have read and understood 
the RadSafe  rules.  These can be found at:  
http://health.phys.iit.edu/radsaferules.html

For  information  on how to subscribe or unsubscribe and other settings
visit:   http://health.phys.iit.edu

_______________________________________________
You  are currently subscribed to the RadSafe mailing list

Before posting a  message to RadSafe be sure to have read and understood 
the RadSafe rules.  These can be found at: 
http://health.phys.iit.edu/radsaferules.html

For  information on how to subscribe or unsubscribe and other settings 
visit:  http://health.phys.iit.edu
_______________________________________________
You  are currently subscribed to the RadSafe mailing list

Before posting a  message to RadSafe be sure to have read and understood 
the RadSafe rules.  These can be found at: 
http://health.phys.iit.edu/radsaferules.html

For  information on how to subscribe or unsubscribe and other settings 
visit:  http://health.phys.iit.edu